These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. How does a drug get to phase III trials? Reynolds T J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084 [No Abstract] [Full Text] [Related]
64. Sipuleucel-T for the treatment of advanced prostate cancer. Frohlich MW Semin Oncol; 2012 Jun; 39(3):245-52. PubMed ID: 22595047 [TBL] [Abstract][Full Text] [Related]
65. The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity. Bot A Int Rev Immunol; 2010 Jun; 29(3):235-8. PubMed ID: 20521923 [No Abstract] [Full Text] [Related]
66. Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov; 2009 Sep; 8(9):685-6. PubMed ID: 19721436 [No Abstract] [Full Text] [Related]
67. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer. Becze E ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750 [No Abstract] [Full Text] [Related]
71. New treatments for metastic prostate cancer. Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400 [TBL] [Abstract][Full Text] [Related]
72. A decade of the Fast Track programme. Reichert JM; Rochon SL; Zhang BD Nat Rev Drug Discov; 2008 Nov; 7(11):885-6. PubMed ID: 18948998 [No Abstract] [Full Text] [Related]
73. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. Peppercorn J; Armstrong A; Zaas DW; George D Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627 [TBL] [Abstract][Full Text] [Related]
74. On access and accountability--two Supreme Court rulings on generic drugs. Boumil MM; Curfman GD N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990 [No Abstract] [Full Text] [Related]
75. Expanding access to investigational drugs for treatment use: a policy analysis and legislative proposal. Winniford A Health Matrix Clevel; 2009; 19(1):205-46. PubMed ID: 19459546 [No Abstract] [Full Text] [Related]
76. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Tanimoto T; Hori A; Kami M N Engl J Med; 2010 Nov; 363(20):1966; author reply 1967-8. PubMed ID: 21067392 [No Abstract] [Full Text] [Related]
77. Food and drug administration expanded access to treatment: implications for oncology patients. Freedman RS; Markman M Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587 [No Abstract] [Full Text] [Related]
78. Cancer vaccines on the horizon. Jones D Nat Rev Drug Discov; 2007 May; 6(5):333-4. PubMed ID: 17539052 [No Abstract] [Full Text] [Related]
79. 21st Century Cures Act-A Cure-All for Patients? Wallis L Am J Nurs; 2016 Jul; 116(7):19-20. PubMed ID: 27336981 [TBL] [Abstract][Full Text] [Related]